Nearly 200 years after the introduction of the stethoscope, the accuracy of a pocket ultrasound device that enables a physician to “look” at a patient’s heart during routine physical exams has been validated for the first time in peer-reviewed research led by Scripps Translational Science Institute (STSI) and Scripps Health.
Roughly the size of a smart phone, the Vscan™ pocket ultrasound used for point of care assessment of heart health could significantly reduce costs from traditional echocardiograms and improve the quality of care. Research was published in the July 5 issue of the Annals of Internal Medicine.
To view Multimedia News Release, go to http://www.multivu.com/mnr/50963-vscan-pocket-ultrasound-echocardiogram-stethoscope
New data revealed that nearly 100 percent (99%) of 200 U.S. primary care physicians surveyed agree that heart disease and stroke are the number one cause of death and disability among type 2 diabetes patients; however, almost 40 percent (36%) of these physicians underestimate the number of patients who die from cardiovascular disease. Furthermore, while people with diabetes are two to four times more likely to have heart disease than people without diabetes, the survey, conducted by Harris Interactive and supported by Merck, found only one out of five (21%) patients (n=664) listed heart attack or heart failure as their biggest worry regarding diabetes complications, and even fewer patients (7%) listed stroke.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/merck/50638/
Bayer HealthCare’s Consumer Care division announced today the introduction of Bayer® Advanced Aspirin, the next generation of aspirin for pain relief. Using the patent-pending Pro-Release™ Technology, Bayer Advanced Aspirin is clinically proven to relieve tough pain twice as fast as previous Bayer® Aspirin tablets.
With the introduction of aspirin in 1899, Bayer offered one of the first widely accessible analgesics, or pain relievers, to consumers. Today, Bayer's overall global Aspirin business continues to grow, and had double-digit, year-on-year sales growth in Q1 2011. Yet, while Bayer continues to be a leader in the category, for many U.S. consumers, Bayer Aspirin is primarily synonymous with cardiovascular use. Now, through a combination of technological innovation and rich analgesic heritage, Bayer is introducing a new standard in aspirin for tough pain relief with Bayer Advanced Aspirin.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/bayer/50414/
A new survey from the nonprofit Gout & Uric Acid Education Society (GUAES) highlights an alarming awareness gap among Americans regarding the risk factors for gout, a chronic, potentially disabling form of arthritis which now affects an estimated 8.3 million Americans. Among the survey findings are that only one in 10 Americans correctly cited cardiovascular disease as a risk factor for gout, while only one in three Americans correctly reported that obesity is a risk factor, and less than one in five reported that diabetes and kidney disease are risk factors. GUAES released the survey findings in advance of its annual Gout Awareness Day on May 22.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/gouteducation/49664/
C. R. Bard, Inc. today announced the publication of RESILIENT trial results by Circulation: Cardiovascular Interventions showing the Bard LifeStent® Vascular Stent improved patency and reduced revascularization rates in patients with moderate-length lesions in the superficial femoral artery (SFA) and proximal popliteal artery compared to patients treated with percutaneous transluminal angioplasty (PTA).
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/bard/44623/
